Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Inhibikase Therapeutics (IKT) Operating Margin (2020 - 2023)

Historic Operating Margin for Inhibikase Therapeutics (IKT) over the last 4 years, with Q4 2023 value amounting to 440356600.0%.

  • Inhibikase Therapeutics' Operating Margin fell 4403497803600.0% to 440356600.0% in Q4 2023 from the same period last year, while for Sep 2024 it was 2006393700.0%, marking a year-over-year decrease of 20063875218800.0%. This contributed to the annual value of 7711.98% for FY2023, which is 69741900.0% up from last year.
  • Latest data reveals that Inhibikase Therapeutics reported Operating Margin of 440356600.0% as of Q4 2023, which was down 4403497803600.0% from 5993.38% recorded in Q3 2023.
  • In the past 5 years, Inhibikase Therapeutics' Operating Margin ranged from a high of 186.56% in Q1 2021 and a low of 440356600.0% during Q4 2023
  • Moreover, its 4-year median value for Operating Margin was 5660.72% (2023), whereas its average is 27549298.5%.
  • As far as peak fluctuations go, Inhibikase Therapeutics' Operating Margin soared by 2000000000bps in 2022, and later plummeted by 2000000000bps in 2023.
  • Over the past 4 years, Inhibikase Therapeutics' Operating Margin (Quarter) stood at 704.66% in 2020, then crashed by -36703bps to 259334.41% in 2021, then soared by 97bps to 6819.64% in 2022, then tumbled by -6457080bps to 440356600.0% in 2023.
  • Its Operating Margin stands at 440356600.0% for Q4 2023, versus 5993.38% for Q3 2023 and 5328.07% for Q2 2023.